MX387402B - Formulaciones eutécticas de clorhidrato de ciclobenzaprina. - Google Patents

Formulaciones eutécticas de clorhidrato de ciclobenzaprina.

Info

Publication number
MX387402B
MX387402B MX2017003644A MX2017003644A MX387402B MX 387402 B MX387402 B MX 387402B MX 2017003644 A MX2017003644 A MX 2017003644A MX 2017003644 A MX2017003644 A MX 2017003644A MX 387402 B MX387402 B MX 387402B
Authority
MX
Mexico
Prior art keywords
cyclobenzaprine hydrochloride
eutectic
eutectic formulations
formulations
cyclobenzaprine
Prior art date
Application number
MX2017003644A
Other languages
English (en)
Spanish (es)
Other versions
MX2017003644A (es
Inventor
Marino Nebuloni
Seth Lederman
Original Assignee
Tonix Pharma Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharma Holdings Ltd filed Critical Tonix Pharma Holdings Ltd
Publication of MX2017003644A publication Critical patent/MX2017003644A/es
Publication of MX387402B publication Critical patent/MX387402B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2017003644A 2014-09-18 2015-09-18 Formulaciones eutécticas de clorhidrato de ciclobenzaprina. MX387402B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462052238P 2014-09-18 2014-09-18
PCT/US2015/051068 WO2016044796A1 (en) 2014-09-18 2015-09-18 Eutectic formulations of cyclobenzaprine hydrochloride

Publications (2)

Publication Number Publication Date
MX2017003644A MX2017003644A (es) 2017-10-31
MX387402B true MX387402B (es) 2025-03-18

Family

ID=55533932

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003644A MX387402B (es) 2014-09-18 2015-09-18 Formulaciones eutécticas de clorhidrato de ciclobenzaprina.

Country Status (12)

Country Link
US (2) US10357465B2 (cg-RX-API-DMAC7.html)
EP (1) EP3193854A4 (cg-RX-API-DMAC7.html)
JP (6) JP6614724B2 (cg-RX-API-DMAC7.html)
CN (2) CN112618494B (cg-RX-API-DMAC7.html)
AU (2) AU2015317336B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017005231A2 (cg-RX-API-DMAC7.html)
IL (2) IL251218B (cg-RX-API-DMAC7.html)
MX (1) MX387402B (cg-RX-API-DMAC7.html)
MY (1) MY186047A (cg-RX-API-DMAC7.html)
SG (2) SG11201701995PA (cg-RX-API-DMAC7.html)
WO (1) WO2016044796A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701637B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2501234T3 (en) 2009-11-20 2017-12-04 Tonix Pharma Holdings Ltd METHODS AND COMPOSITIONS FOR TREATING SYMPTOMS CONNECTED WITH POSTTRAUMATIC LOAD RESPONSE USING CYCLOBENZAPRINE
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
CN110152005B (zh) 2013-03-15 2023-08-04 通尼克斯制药控股有限公司 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂
CN112618494B (zh) 2014-09-18 2023-06-30 通尼克斯制药控股有限公司 环苯扎林盐酸盐的低共熔混合物配制剂
CA3083341C (en) 2017-12-11 2024-05-28 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
BR112021003107A2 (pt) * 2018-08-20 2021-05-11 Tonix Pharma Holdings Limited métodos de tratamento de transtorno de estresse agudo e transtorno de estresse pós-traumático
NL2023661B1 (en) * 2019-08-19 2021-04-21 Seranovo Holding B V Pharmaceutical Eutectic Salt Formulation
JP7780447B2 (ja) * 2020-04-08 2025-12-04 トニックス ファーマシューティカルズ ホールディング コーポレイション 性機能障害のシクロベンザプリン処置
WO2022109218A1 (en) * 2020-11-20 2022-05-27 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for alcohol use disorder
US20240024256A1 (en) * 2020-12-07 2024-01-25 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for fibromyalgia
US20240415789A1 (en) 2021-10-06 2024-12-19 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients
AU2023286504A1 (en) 2022-06-21 2025-01-16 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc)
WO2025160302A1 (en) 2024-01-25 2025-07-31 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for acute stress reaction or acute stress disorder

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968507A (en) 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5498421A (en) 1993-02-22 1996-03-12 Vivorx Pharmaceuticals, Inc. Composition useful for in vivo delivery of biologics and methods employing same
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999018937A1 (en) * 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
DE69904465T2 (de) 1998-05-14 2003-10-02 Alza Corp., Mountain View Therapie von depressionen
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
EP1202721A1 (en) 1999-08-13 2002-05-08 Vela Pharmaceuticals Inc. Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof
CA2380432A1 (en) 1999-08-13 2001-02-22 Iredell W. Iglehart, Iii Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
WO2001089476A1 (en) 2000-05-19 2001-11-29 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
NZ532583A (en) 2001-11-05 2006-12-22 Krele Pharmaceuticals Compositions and methods for increasing compliance using aldehyde dehydrogenase inhibitors ( ALDH ) such as disulfiram and monoamine oxidase B inhibitors ( MAOB ) such as selegiline
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7105486B2 (en) 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
CA2503381A1 (en) 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
JP2006524632A (ja) 2002-12-09 2006-11-02 アメリカン バイオサイエンス、インコーポレイテッド 組成物及び薬物送達方法
SI1644019T2 (en) 2003-05-29 2018-04-30 Shire Llc AMPHETAMINE COMPOUNDS COMPOUNDS TO ABUSE
WO2005042501A1 (en) 2003-11-03 2005-05-12 Warner-Lambert Company Llc Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
US20050143350A1 (en) 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
JP2007516259A (ja) 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
KR20130116378A (ko) 2004-02-17 2013-10-23 트랜스셉트 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의 사용 방법
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US20070196364A1 (en) * 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7532935B2 (en) 2005-07-29 2009-05-12 Cyberonics, Inc. Selective neurostimulation for treating mood disorders
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20080146672A1 (en) 2006-12-08 2008-06-19 Denton Marcia Marye Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue
JP2010530874A (ja) 2007-06-22 2010-09-16 メルク・シャープ・エンド・ドーム・コーポレイション ６，５−ピロロピペリジンタキキニン受容体アンタゴニスト
CN101951912A (zh) 2007-07-23 2011-01-19 辛诺西亚治疗公司 创伤后应激障碍的治疗
US20090060983A1 (en) 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
PL2200588T3 (pl) 2007-09-25 2019-09-30 Solubest Ltd. Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
US20100247649A1 (en) 2007-10-30 2010-09-30 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
US20090148532A1 (en) 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
JP5380909B2 (ja) 2008-05-30 2014-01-08 株式会社ブリヂストン 金型及び樹脂発泡成形品の成形方法
US20100266682A1 (en) 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
US20100247586A1 (en) 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
EP2233134A1 (en) 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
US8871263B2 (en) 2009-09-24 2014-10-28 Mcneil-Ppc, Inc. Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder
DK2501234T3 (en) 2009-11-20 2017-12-04 Tonix Pharma Holdings Ltd METHODS AND COMPOSITIONS FOR TREATING SYMPTOMS CONNECTED WITH POSTTRAUMATIC LOAD RESPONSE USING CYCLOBENZAPRINE
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
PT2611440T (pt) 2010-09-01 2017-04-26 Tonix Pharmaceuticals Inc Tratamento para a dependência de cocaína
US11998516B2 (en) * 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
HUE060175T2 (hu) * 2012-06-15 2023-02-28 Tonix Pharma Holdings Ltd Transzmukózális felszívódásra szolgáló készítmények és módszerek
CN110152005B (zh) * 2013-03-15 2023-08-04 通尼克斯制药控股有限公司 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂
CN112618494B (zh) * 2014-09-18 2023-06-30 通尼克斯制药控股有限公司 环苯扎林盐酸盐的低共熔混合物配制剂

Also Published As

Publication number Publication date
IL277814B (en) 2021-12-01
CA2961822A1 (en) 2016-03-24
NZ730379A (en) 2023-10-27
JP6717902B6 (ja) 2020-08-05
BR112017005231A2 (pt) 2018-03-13
MX2017003644A (es) 2017-10-31
NZ768064A (en) 2023-10-27
AU2015317336B2 (en) 2021-01-21
JP2017532374A (ja) 2017-11-02
SG11201701995PA (en) 2017-04-27
WO2016044796A1 (en) 2016-03-24
US10357465B2 (en) 2019-07-23
JP2023126486A (ja) 2023-09-07
CN107072968A (zh) 2017-08-18
JP2018193409A (ja) 2018-12-06
US11026898B2 (en) 2021-06-08
AU2020289838B2 (en) 2022-11-24
EP3193854A4 (en) 2018-05-02
SG10201902203VA (en) 2019-04-29
CN107072968B (zh) 2021-01-12
EP3193854A1 (en) 2017-07-26
JP2022001605A (ja) 2022-01-06
JP6717902B2 (ja) 2020-07-08
MY186047A (en) 2021-06-17
IL251218A0 (en) 2017-05-29
AU2015317336A1 (en) 2017-04-13
AU2020289838A1 (en) 2021-01-28
JP2025107355A (ja) 2025-07-17
ZA201701637B (en) 2020-11-25
JP6614724B2 (ja) 2019-12-04
JP2020059757A (ja) 2020-04-16
CN112618494A (zh) 2021-04-09
IL277814A (en) 2020-11-30
IL251218B (en) 2020-10-29
CN112618494B (zh) 2023-06-30
US20190336458A1 (en) 2019-11-07
US20170281568A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
MX387402B (es) Formulaciones eutécticas de clorhidrato de ciclobenzaprina.
MY196014A (en) Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride
EP3606559C0 (en) BIOORTHOGONAL COMPOSITIONS
DK3256138T3 (da) Farmaceutiske sammensætninger omfattende meloxicam
DK3529248T3 (da) Farmaceutiske sammensætninger
MX376083B (es) Formas de dosificacion solidas de palbociclib.
SI4070787T1 (sl) Farmacevtske formulacije
EP3641771A4 (en) PHARMACEUTICAL COMPOSITIONS
DK3655038T3 (da) Farmaceutisk sammensætning
BR112016021012A2 (pt) composições farmacêuticas de compostos terapeuticamente ativos.
EP3316685A4 (en) Lyophilized Pharmaceutical Compositions
LT3405178T (lt) Formuluotės / kompozicijos, apimančios btk inhibitorių
DK3583943T3 (da) Farmaceutisk sammensætning
DK3411008T3 (da) Sammensætninger omfattende aktive solbeskyttelsesmidler med polyhydroxyfulleren
DK3280447T3 (da) Farmaceutiske formuleringer
LT3389633T (lt) Farmacinės kompozicijos, apimančios fenilaminopirimidino darinį
IN2014CH00840A (cg-RX-API-DMAC7.html)
SMT202400478T1 (it) Composizione farmaceutica
BR112017024126A2 (pt) composições farmacêuticas e uso das mesmas
DK3324736T3 (da) Hidtil ukendt spot-on-aktivstofformulering
EA201691422A1 (ru) Перорально распадающиеся таблетированные составы мемантина
EP3654955C0 (en) PHARMACEUTICAL COMPOSITIONS
DK3558261T3 (da) Farmaceutiske sammensætninger omfattende safinamid
DK3424500T3 (da) Farmaceutisk sammensætning, der omfatter famitinib
IN2014CH00035A (cg-RX-API-DMAC7.html)